Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
Complete Title: A Phase 3 Randomized, Placebo-Controlled COG ACCL2031, Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Trial Phase: III
Investigator: Sarah Leary
This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or have come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary brain tumor.
Keywords:
- Brain Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
III
Sarah Leary
RG1122319
NCT04939597
A Phase 3 Randomized, Placebo-Controlled COG ACCL2031, Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Brain Cancer